tretinoin has been researched along with Mycosis-Fungoides* in 17 studies
1 trial(s) available for tretinoin and Mycosis-Fungoides
Article | Year |
---|---|
Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.
Thirty-nine patients with mycosis fungoides in various stages or Sézary syndrome were treated with isotretinoin and 29 with etretinate as single drug therapy. Complete remission within 2 months was obtained with isotretinoin in 8 cases (21%) and partial remission in another 15 cases (38%). Etretinate induced complete remission in 5 cases (21%) and partial remission in 11 (46%). Only 1 case with Sézary syndrome went into partial remission. The first sign of remission occurred in 2 to 4 weeks. During continued treatment remissions could not always be maintained. Isotretinoin and etretinate were considered to be of equal potency in the treatment of mycosis fungoides. Topics: Drug Eruptions; Etretinate; Humans; Isotretinoin; Lymphatic Metastasis; Mycosis Fungoides; Remission Induction; Sezary Syndrome; Skin Neoplasms; Tretinoin | 1987 |
16 other study(ies) available for tretinoin and Mycosis-Fungoides
Article | Year |
---|---|
Successful treatment of extensive splanchnic vein thrombosis in a patient with mycosis fungoides.
A 33-year-old man of a Middle Eastern origin presented to us with abdominal pain and distension secondary to refractory ascites of 1-month duration. The patient had a history of taking oral retinoic acid 25 mg for 4 months for mycosis fungoides. Investigations revealed thrombosis of hepatic veins with extensive thrombosis of the porto-mesenteric axis. A combination of transjugular intrahepatic portosystemic shunt, balloon angioplasty and thrombolysis with recombinant tissue plasminogen activator was successfully used to treat his condition. Topics: Abdominal Pain; Adult; Angioplasty, Balloon; Antineoplastic Agents; Ascites; Humans; Male; Mycosis Fungoides; Portasystemic Shunt, Transjugular Intrahepatic; Splanchnic Circulation; Stents; Tissue Plasminogen Activator; Treatment Outcome; Tretinoin; Venous Thrombosis | 2018 |
Tumour-stage mycosis fungoides regressing with milia and pustules after total skin electron beam therapy.
Topics: Acute Generalized Exanthematous Pustulosis; Aged; Diagnosis, Differential; Humans; Keratolytic Agents; Keratosis; Male; Mycosis Fungoides; Neoplasm Staging; Skin Neoplasms; Tretinoin | 2017 |
Alitretinoin treatment in mycosis fungoides with CD30-positive large cell transformation.
Topics: Alitretinoin; Antineoplastic Agents; Cell Transformation, Neoplastic; Humans; Ki-1 Antigen; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tretinoin | 2017 |
Treatment of cutaneous T-cell lymphoma with oral alitretinoin.
Cutaneous T-cell lymphoma (CTCL) is a potentially life-limiting malignant disease. Treatment strategies in CTCL aim at disease control and remission with the lowest possible side-effects.. Recent reports suggest that the new vitamin A derivative alitretinoin might be a well-tolerated treatment option.. We analysed the files of 11 CTCL patients with mycosis fungoides (n = 10) or Sézary syndrome (n = 1), who were treated with oral alitretinoin alone or in combination with standard treatment based on individual off-label treatment decisions. Patients had been monitored every 4-8 weeks with skin examination and laboratory analyses.. Ten of 11 patients (90.9%) showed a marked improvement of their CTCL skin lesions and no progress of the disease during treatment with alitretinoin, one patient showed no response to the treatment (9.1%). Four of the responding patients (40.0%) had a complete response and 6 (60.0%) had a partial response. Average time to response was 2.5 months. Duration of treatment varied depending on whether patients had reached complete or partial remission. In general, alitretinoin was well tolerated. One of 11 patients developed high non-fasting average serum cholesterol (>300 mg/dL) and 1/11 a mean non-fasting triglyceride value >500 mg/dL. In 3/11 patients, thyroid-stimulating hormone declined without clinical symptoms during treatment, with one of the patients also showing a decreased thyroxin level.. In our group of CTCL patients we noticed a low rate of side-effects and an overall good clinical response to treatment with alitretinoin. Further studies are required to substantiate this early clinical observation. Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alitretinoin; Antineoplastic Agents; Calcineurin Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Off-Label Use; Photopheresis; PUVA Therapy; Retreatment; Retrospective Studies; Sezary Syndrome; Treatment Outcome; Tretinoin | 2015 |
Alitretinoin in the treatment of palmoplantar mycosis fungoides: a new and promising therapeutic approach.
Topics: Alitretinoin; Antineoplastic Agents; Female; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Treatment Outcome; Tretinoin | 2015 |
Treatment of 2 patients with mycosis fungoides with alitretinoin.
Topics: Alitretinoin; Antineoplastic Agents; Humans; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tretinoin | 2012 |
Possible benefit of oral alitretinoin in T-lymphoproliferative diseases: a report of two patients with palmoplantar hyperkeratotic-rhagadiform skin changes and mycosis fungoides or Sézary syndrome.
Topics: Aged; Alitretinoin; Antineoplastic Agents; Humans; Keratoderma, Palmoplantar; Male; Mycosis Fungoides; Photopheresis; Sezary Syndrome; Skin Neoplasms; Treatment Outcome; Tretinoin | 2009 |
Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients.
Concurrent with a phase-II trial of 4HPR in patients with various cancers, we studied the plasma pharmacokinetics of both 4HPR and its major metabolite 4MPR as well as the effect of 4HPR administration on plasma retinol concentrations using a simple, specific and sensitive HPLC procedure. Initial estimates of plasma pharmacokinetic parameters after oral administration of 4HPR (300 mg/day) [corrected] in 3 cancer patients were the following: 4HPR, t beta 1/2 = 13.7 hr, AUC = 3.49 micrograms.hr/ml, CL = 56.57 L/hr/m2; 4MPR, t beta 1/2 = 23.0 hr, AUC = 1.15 micrograms.hr/ml, CL = 239.29 L/hr/m2. We also found that oral administration of 4HPR resulted in a rapid, profound and significant reduction in plasma retinol concentrations. The mean plasma retinol concentrations for 9 patients decreased 60% from baseline to below 200 ng/ml within 1-2 weeks of 4HPR dosing initiation. In addition, there was a concurrent, significant reduction in plasma retinol-binding protein levels in these patients. The mechanism whereby 4HPR reduces plasma retinol levels in vivo has not been determined. The addition of 4HPR to pooled human plasma at 37 degrees C in vitro did not reduce endogenous retinol levels, suggesting no direct chemical interaction between these 2 retinoids. Topics: Administration, Oral; Breast Neoplasms; Chromatography, High Pressure Liquid; Drug Evaluation; Fenretinide; Humans; Melanoma; Mycosis Fungoides; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Tretinoin; Vitamin A | 1989 |
Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides).
Retinoids, including isotretinoin, have demonstrated antiproliferative and antineoplastic activity in laboratory and clinical trials. In a phase II trial, 25 patients with extensive mycosis fungoides were evaluated for response to isotretinoin. There was a 44% (11 patients) objective clinical response rate with three clinical complete responses without concomitant evidence of pathologic clearing of the disease. An additional 24% (six patients) showed a minor degree of clinical improvement. The median time to response was two months (range, 0.5 to eight months) and the median response duration was eight months or longer (range, one to 25 months). Chronic toxic reactions consisted primarily of drying of the skin and mucous membranes and resulted in dose reduction in the majority of patients. It is concluded that isotretinoin produces significant clinical benefit to some patients with mycosis fungoides. Topics: Adult; Aged; Aged, 80 and over; Drug Eruptions; Drug Evaluation; Female; Humans; Isotretinoin; Male; Middle Aged; Mycosis Fungoides; Sezary Syndrome; Skin Neoplasms; Tretinoin; Triglycerides | 1987 |
Treatment of mycosis fungoides with isotretinoin.
A 56-year-old man with a 7-year history of well-documented mycosis fungoides is reported. Because the patient was a treatment failure with topical nitrogen mustard due to severe allergic contact dermatitis, and because of recent reports of the efficacy of retinoid compounds, he was treated with a 6-month course of isotretinoin with total clearing of his skin lesions. Previous case reports and possible mechanisms of action are reviewed. Topics: Humans; Immunity; Isotretinoin; Male; Middle Aged; Mycosis Fungoides; Nitrogen Mustard Compounds; Skin Neoplasms; Tretinoin | 1986 |
Retinoid dermatitis mimicking progression in mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Group.
A dermatitis occurring during the treatment of mycosis fungoides with A vitamin analogues (13-cis-retinoic acid and etretinate) and mimicking a progression of the disease is described. It is considered to be a skin reaction due to the treatment. Its benign nature is revealed by histology showing a lymphocytic infiltrate without any atypical sign. Topics: Aged; Diagnosis, Differential; Drug Eruptions; Etretinate; Humans; Isotretinoin; Middle Aged; Mycosis Fungoides; Skin; Skin Neoplasms; Tretinoin | 1985 |
13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group.
Twenty patients with mycosis fungoides and four with Sézary's syndrome were treated with 13-cis-retinoic acid as single therapy in an initial dose of 1 to 2 mg per kg body weight in most cases. Complete remission in mycosis fungoides was obtained in six cases (33%) and partial remission in another ten cases (50%). No convincing response was observed in three cases, and progression of limited nodular lesions occurred in one case. In cases responding to treatment the first sign of remission was observed within two to four weeks. Our short-term experience is that the drug is effective in early as well as advanced stages of mycosis fungoides. Patients with Sézary's syndrome, however, did not respond to the same extent. Topics: Adult; Aged; Female; Humans; Isomerism; Isotretinoin; Male; Middle Aged; Mycosis Fungoides; Sezary Syndrome; Skin Neoplasms; Time Factors; Tretinoin | 1984 |
Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid.
Four patients with refractory cutaneous T-cell lymphoma (mycosis fungoides) were treated with 13-cis-retinoic acid. Near complete clearing of extensive tumours and plaques was seen in one patient, who remains in partial remission with continued improvement after fifteen months. Two patients showed improvement in pruritus and 50% reduction in plaques by four and six weeks, respectively. The fourth patient had improvement in pruritus and clearing of plaques, but dryness and scaling necessitated reduction and eventually withdrawal of the treatment. Topics: Adult; Aged; Female; Humans; Isotretinoin; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Time Factors; Tretinoin | 1983 |
Treatment of mycosis fungoides with isotretinoin.
Topics: Humans; Isotretinoin; Mycosis Fungoides; Tretinoin | 1983 |
[Retinoid oral photochemotherapy (RePUVA) as a combination treatment of mycosis fungoides].
Topics: Administration, Oral; Adult; Etretinate; Humans; Mycosis Fungoides; Photochemotherapy; PUVA Therapy; Skin Neoplasms; Tretinoin | 1983 |
[A case of mycosis fungoides with tumoral manifestations, treated with RO 10-9359 (Tigáson)].
Topics: Etretinate; Female; Humans; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tretinoin; Vitamin A | 1982 |